Suppr超能文献

静脉药物滥用者感染性心内膜炎的手术治疗。

Surgical treatment of infective endocarditis in intravenous drug abusers.

机构信息

Department of Thoracic and Cardiovascular Surgery, West German Heart and Vascular Center, University of Duisburg-Essen, Essen, Germany.

Department of Medicine, Faculty of Medicine, Imperial College London, London, UK.

出版信息

J Cardiothorac Surg. 2021 Apr 20;16(1):97. doi: 10.1186/s13019-021-01491-1.

Abstract

BACKGROUND

Despite current progress in antibiotic therapy and medical management, infective endocarditis remains a serious condition presenting with high mortality rates. It also is a life-threatening complication in patients with a history of chronic intravenous drug abuse. In this study, we analyzed our institutional experience on the surgical therapy of infective endocarditis in patients with active intravenous drug abuse. The aim of the study is to identify the predictive factors of mortality and morbidity in this subgroup of patients.

METHODS

Between 2007 and 2020, a total of 24 patients (7 female, mean age 38.5 ± 8.7) presenting with active intravenous drug abuse underwent a surgical treatment for the infective endocarditis at out center. The primary endpoint was survival at 30th day after the surgery. The secondary composite endpoint included freedom from death, recurrent endocarditis, re-do surgery, and postoperative stroke during the follow-up period. Mean follow-up was 4.2 ± 4.3 years.

RESULTS

Staphylococcus species was the most common pathogen detected in the preoperative blood cultures. Infection caused by Enterococcus species as well as liver function impairment were identified as mortality predictor factors. Logistic EuroSCORE and EusoSCORE-II were also predictive factors for mortality in univariate analysis. Survival at 1 and 3 years was 78 and 72% respectively. Thirty-day survival was 88%. 30-day freedom from combined endpoint was 83% and after 1 and 3 years, 69 and 58% of the patients respectively were free from combined endpoint. Five patients (20.8%) were readmitted with recurrent infective endocarditis.

CONCLUSION

In patients presenting with active intravenous drug abuse, treatment of infective endocarditis should be performed as aggressively as possible and should be followed by antibiotic therapy to avoid high mortality rates and recurrent endocarditis. Early intervention is advisable in patients with an infective endocarditis and enterococcus species in the preoperative blood cultures, liver function deterioration as well as cardiac function impairment. Attention should be also payed to addiction treatment, due to the elevated relapse rate in patients who actively inject drugs. However, larger prospective studies are necessary to support our results. As septic shock is the most frequent cause of death, new treatment options, e.g. blood purification should be evaluated.

摘要

背景

尽管目前抗生素治疗和医学管理取得了进展,但感染性心内膜炎仍然是一种死亡率较高的严重疾病。它也是慢性静脉药物滥用患者的一种危及生命的并发症。在这项研究中,我们分析了我们机构在有活性静脉药物滥用患者的感染性心内膜炎手术治疗方面的经验。研究的目的是确定该亚组患者死亡和发病的预测因素。

方法

2007 年至 2020 年期间,我院共收治 24 例(7 例女性,平均年龄 38.5±8.7 岁)有活性静脉药物滥用的感染性心内膜炎患者,接受手术治疗。主要终点是术后 30 天的存活率。次要复合终点包括随访期间无死亡、复发性心内膜炎、再次手术和术后中风。平均随访时间为 4.2±4.3 年。

结果

术前血培养中最常见的病原体是葡萄球菌属。肠球菌属感染和肝功能损害被确定为死亡预测因素。Logistic EuroSCORE 和 EusoSCORE-II 在单因素分析中也是死亡的预测因素。1 年和 3 年生存率分别为 78%和 72%。30 天生存率为 88%。30 天无复合终点的比例为 83%,1 年和 3 年后,分别有 69%和 58%的患者无复合终点。5 例(20.8%)患者因复发性感染性心内膜炎再次入院。

结论

对于有活性静脉药物滥用的患者,应尽可能积极地治疗感染性心内膜炎,并在术后进行抗生素治疗,以避免高死亡率和复发性心内膜炎。对于术前血培养中出现肠球菌属、肝功能恶化以及心功能损害的感染性心内膜炎患者,应早期进行干预。由于活跃注射药物的患者复发率较高,因此还应注意成瘾治疗。然而,需要更大规模的前瞻性研究来支持我们的结果。由于感染性休克是最常见的死亡原因,应评估新的治疗选择,例如血液净化。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验